Medical studies for chronic disease are often interested in the relation between longitudinal risk factor profiles and individuals' later life disease outcomes. These profiles may typically be subject to intermediate structural changes due to treatment or environmental influences. Analysis of such studies may be handled by the joint model framework. However, current joint modeling does not consider structural changes in the residual variability of the risk profile nor consider the influence of subjectspecific residual variability on the time-to-event outcome. In the present paper, we extend the joint model framework to address these two heterogeneous intra-individual variabilities. A Bayesian approach is used to estimate the unknown parameters and simulation studies are conducted to investigate the performance of the method. The proposed joint model is applied to the Framingham Heart Study to investigate the influence of anti-hypertensive medication on the systolic blood pressure variability together with its effect on the risk of developing cardiovascular disease. We show that anti-hypertensive medication is associated with elevated systolic blood pressure variability and increased variability elevates risk of developing cardiovascular disease.
Introduction
Medical studies for chronic diseases such as cancer, human immunodeficiency virus (HIV), and cardiovascular diseases (CVD), frequently involve studying longitudinal measurements of certain risk factors in relation to an individual's later life time-to-event disease outcome.
The trajectories or the longitudinal profiles of the risk factors, which describe the progression of the risk factor variables over time, play an important role in preventive healthcare. tor, changes in growth rate, and changes in risk factor variability. All these changes may happen simultaneously and they may have different effects on the disease outcome. This is commonly observed in, for example, the field of life course epidemiology (Ben-Shlomo and Kuh and others, 2002; Kuh and Shlomo, 2004) .
To address research questions about the association of the longitudinal profiles and the event times, statistical analysis is often conducted with some form of joint model. These joint models often assume either the existence of a set of low-dimensional unobserved time-independent variables that vary across individuals and operate underneath both the longitudinal profile and the survival time (Wulfsohn and Tsiatis, 1997) , or the risk of event occurrence is directly associated with the latent (functions of) smooth longitudinal profile (Rizopoulos, 2012; Papageorgiou and others, 2019) . They focus on how the levels of the smooth profile are associated with prognosis (Tsiatis and Davidian, 2004) . Recent advances in joint models extended single longitudinal profiles to multiple profiles with possible extension to different risk factor types (Larsen, 2004; Chi and Ibrahim, 2006; Andrinopoulou and others, 2014; Musoro and others, 2015; Proust-Lima and others, 2014) .
Nevertheless, the main associations between the longitudinal profiles and the time-to-event outcomes still closely follow the two approaches described above. Whilst, relations between other features of the longitudinal profiles, such as the intra-individual variability, and the time-to-event outcome is less frequently discussed.
The present paper is motivated by the Framingham Heart Study (Dawber and others, 1951) , an observational cohort study across multiple generations aimed to identify the common factors or characteristics that contribute to CVD. In the past, the Framingham Heart Study data has been used to investigate the associations between various blood pressure components, including systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP), with the risk of developing CVD (see for example Levy, 1999; Kannel, 1996; others, 2014, 2015; Nayor and others, 2018) . In addition, the Framingham Heart Study data has been used to study the hemodynamic patterns of age-related changes in blood pressure (Kannel and others, 1971; others, 1999, 2009 ). Hathaway and D'Agostino (1993) reported a significant association between variance of SBP and subsequent coronary heart disease among a group of 516 women in the Framingham Heart Study. Their approach resembled a two-step joint model (an earlier versions of the joint model framework). Summary statistics based on regression of the SBP on age and the original observed repeated measurements of SBP were considered as independent predictors in a logistic regression model for coronary heart disease. This twostep approach is however known to produce biased estimates in the joint model literature (Tsiatis and Davidian, 2004; Rizopoulos, 2012) .
In the field of CVD, it has been established that increased long-term SBP variability was associated with risk of CVD events and mortalities (Stevens and others, 2016; Sponholtz and others, 2019) . However, methods for evaluating SBP variabilities are diverse, which includes standard deviation, coefficient of variation, average real variability (sum of absolute difference between two consecutive SBPs) (Mena and others, 2005) , and variability independent of mean (Rothwell and others, 2010) . Several methodological issues have been raised related to the analysis and understanding of SBP variability (Stevens and others, 2016) . First of all, analysis of variability need to take into account the correlation between high mean blood pressure and high variability. Secondly, variabilities based on the repeated measurements during follow-up are frequently used in studies as a baseline risk factor, which potentially introduces immortal bias and other related problems that joint model attempts to address.
In the present paper, we extended the commonly used joint model (Rizopoulos, 2012) for a longitudinal profile with heterogenous intra-individual variabilities and relate the risk of developing certain disease to the intra-individual variability in combination with disruptive risk profiles due to treatment interventions. A partial likelihood is proposed which is proportional to the complete likelihood where the initiation of treatment is assumed to be associated with the observed value of the longitudinal profile but does not share parameters with the longitudinal and survival models. Monte Carlo Markov Chain (MCMC) algorithm was used to estimate the parameters in the longitudinal and the survival models.
The rest of this paper is organized as follow. In Section 3, we propose a joint model for the longitudinal profile, the treatment initiation, and the survival outcome. Furthermore, we construct the likelihood function for the proposed model which leads to the partial likelihood function for the longitudinal and survival outcome only. We provide the prior distributions for the parameters of interests and the posterior sampling scheme in Section 4.
In Section 5, a simulation study is described. In Section 6, the proposed joint model is fitted to the Framingham Heart Study data and the effect of the SBP variability on the risk of developing CVD and the effect of the anti-hypertensive medication on the SBP variability are estimated. Discussion follows in Section 7. Preliminary analysis of the Framingham Heart Study data was conducted by fitting the subject-specific growth model (2) described later in Section 3 without heteroskedasticity (i.e., intra-individual variance of the SBP σ 2 ij = σ 2 0 ) to the data. Results indicate that the residual variance across individuals for SBP before treatment is heteroskedastic. Figure 1 visualizes that the SBP variability before treatment differs between two individuals. In addition, it can be shown that the estimated residual variance for SBP before treatment does not follow a chi-square distribution. Under homoskedasticity, it was expected that the sum of squares of the q i residuals (q i − 1)s 2 0i for individual i before treatment, divided by the variance of all residuals before treatment σ 2 0 , has a chi-square distribution with q i − 1 degrees of freedom:
Motivating example
This distributional assumption remains approximately true for large numbers of participants when σ 2 0 is replaced by its estimateσ 2 0 over all residuals before treatment. However, Figure 2 demonstrates a clear violation of normality for the transformation Φ −1 χ 2 q i −1 ((q i − 1)s 2 0i /σ 2 0 ) (Anderson-Darling A 2 = 16.11, p < 0.005). Clearly, the variability in the variances exceeds the variance of the chi-square distribution. Another important observation is that the intraindividual variability changes after treatment within patients. The residual variance seems to increase which is depicted in Figure 3 where the histogram of the residual variances for SBP before and after treatment are visualized.
Methods

Treatment and longitudinal profile
Let Y i = (Y i1 , . . . , Y i,m i ) denote the vector of repeated measurements of the longitudinal profile for individual i (i = 1, . . . , N ) at measurement occasions t ij with j = 0, 1, . . . , m i and t i0 = 0 indicating the baseline, and Z i = (Z i1 , . . . , Z im i ) the corresponding treatment indicator with Z ij = 1 meaning treatment is administrated at the jth measurement occasion, and 0 otherwise. Assuming that treatment is administrated based on the observed value of the longitudinal profile, as well as the previous treatment condition of the individual, we may assume that
where Φ is the standard normal cumulative distribution function and α = (α 0 , α 1 ) are unknown parameters related to the treatment process. Implicitly, we assume that Y ij precedes Z ij , namely the observed value of Y ij is used to determine treatment administration at measurement j. In this treatment-model, the only factors that determines the initiation of treatment is the most recent measurement of the observed longitudinal profile and previous treatment condition. This may be a simplification of a real-life decision processes, since other measured factors could contribute to the treatment decision, but our treatment-model can be extended to include other factors. It should be noted that, when an individual is already under treatment Z ij−1 = 1, treatment will not stop, namely P (Z ij = 1|Y ij , Z ij−1 = 1) = 1 as implied by the formulation of model (1). This may be realistic when medication is used for chronic conditions. Thus we will not consider the possibility of treatment cessation in the present paper.
For the longitudinal profile, a subject-specific linear growth model is specified as
where the random term
, σ 2 0 the mean residual variance before treatment over all individuals, t ij is the time point of the jth measurement occasion for 
Survival time and event
Let T i = min(T * i , C i ) be the observed survival time for individual i taking the value of the true survival time T * i if the event is observed and otherwise taking the value of the censoring time C i . The hazard rate λ i (t) is specified as
and γ 0 , γ 1 their corresponding effects on the hazard function, respectively, and λ 0 (t) the baseline hazard function of a parametric survival distribution such as the Weibull distribution. In addition, the event indicator is denoted by
The survival model implies that the hazard ratio between two individuals i and j with the same conditional mean profile but different variabilities would be equal to
Furthermore, no direct treatment effect is specified in the survival model. This reflects the modeling assumption that the effect of the treatment is completely being mediated by the structural changes in the longitudinal profile. Alternatively, we can also incorporate a direct effect of the treatment into the hazard function.
The likelihood function
The joint distribution of the longitudinal pair (Y i , Z i ) and the survival pair
We will further assume, that conditional on the latent variables r i , the survival outcome is independent of the longitudinal profile. As a consequence, the joint distribution can be expressed as
Since the treatment model (1) does not depend on the latent variables r i , the term f (Z ij |Y i,j−1 , Z i,j−1 ) moved outside the integral. This remains true when we would enhance it with additional risk factors, earlier values from the longitudinal data or include the treatment indicator in the hazard function. It should be noted that it is more realistic to have the treatment model depend on Y ij instead of r i since treatment interventions would be based on the observations rather than the expected observations. If we further assume that the treatment model does not share any common unknown parameters with the longitudinal and survival models (ignorability), the unknown parameters in the treatment model can be ignored. Therefore, to obtain the estimates of the unknown parameters in the longitudinal and survival models, the following partial likelihood for individual i is considered:
where φ(·) is the standard normal density function. Furthermore, the integration of the hazard function with respect to time in the survival model is approximated by
using an event history formulation similar to Henderson and others (2000) , where Λ 0 is the cumulative baseline hazard function. We implicitly assumed a piece-wise constant function for both µ ij and σ ij within the interval [t ij , t i,j+1 ) and which is left-continuous with respect to time.
Unfortunately, direct maximization of the partial likelihood may yield biased estimates for γ 1 the effect of the variability in the hazard function. The reason is that the maximum likelihood estimator tends to underestimate the variance components of the longitudinal profile in small sample cases due to the failure to account for a reduction in degrees of freedom associated with fixed effects parameters. The underestimated variance component of the latent variable c i will consequently lead to a underestimated σ 2 ij which in turn will cause overestimation of γ 1 in the survival model. Therefore, a restricted maximum likelihood (REML) estimator is needed to transform the partial likelihood such that the distribution of the error construct is unrelated to those parameters. However, finding a transformation of the data consisted of both longitudinal profile and survival outcome is not trivial. One alternative can be derived using a Bayesian formulation by introducing a flat prior for the fixed effect parameters. This approach was considered by Harville (1974, 1976) and Dempster and others (1981) and has been shown to coincide with the REML estimates. Furthermore, the empirical bayes estimates of the latent variables are the estimated means of the posterior distributions (Laird and Ware, 1982) . Therefore, we take a Bayesian approach to estimate the parameters of interests by introducing prior distributions to the fixed effect parameters.
Sampling posterior distribution via MCMC
Unbounded uniform priors on (−∞, ∞) are specified for all fixed effects parameters β 0 , β 1 , β 2 , β 3 , ν, γ 0 , γ 1 independent of each other. A truncated half-normal prior was assigned to σ 0 . For the parameters involved in the baseline survival distribution (e.g., Weibull parameters), bounded uniform priors are specified. For instance, for the shape and scale parameters of the Weibull baseline, we considered a [0, U ]-uniform distribution with U >>Û . HereÛ is the estimated parameter value obtained from a standalone fit of the survival model to the data. For the covariance matrix Σ, we decompose the prior into a scale and a correlation matrix. Specifically, Σ = diag(τ ) Ω diag(τ ), where the vector τ is a vector of scale coefficients τ k = Σ k,k of the (k, k)-diagonal of the covariance matrix, Ω the correlation matrix with its (p, q) entry Ω p,q = (τ p τ q ) −1 Σ p,q . A half-Cauchy distribution C + (0, 2.5) is specified as the prior for τ k , and a LKJ correlation distribution (Lewandowski and others, 2009 ) is specified for the correlation matrix Ω (Gelman and others, 2013) . The primary motivation for adopting this weakly-informative prior distribution for τ k is to constrain the intra-individual variance before and after treatment away from very large values in case of insufficient number of follow-up measurements for some individuals (Gelman and others, 2006) . Further reparametrization of τ and Cholesky factorization of the correlation matrix Ω are used only for computational purposes. Posterior samples are generated using the No U-Turn Sampler (NUTS), an extension to the Hamiltonian Monte Carlo algorithm (Hoffman and Gelman, 2014) .
Simulations
Data generation
The simulated data is generated according to the three models described in Section 3. For 
Results
The results of the simulation are shown in Table 1 and 2. In Table 1 , the mean, SD, and MSE of the fixed effect and τ k estimates were shown. All parameters were estimated without bias except for τ 3 and τ 4 but with a relative bias of at most 5 to 10%. Empirical standard errors for β 0 , β 2 , τ 1 , and τ 3 were relatively large and their coverage probabilities were somewhat conservative (i.e., below the nominal value) but still within the range of simulation (Monte Carlo) variability. In Table 2 , the average estimates and the corresponding empirical standard error of the covariance matrix Σ is displayed. In addition, Table 3 shows the mean, SD, and coverage probability of the estimates for the cholesky factor (upper triangular matrix) of Σ. Compared to the true value used in the simulation, covariance estimates related to the after treatment periods (e.g., cov(β 0 , β 2 ), var(c i )) were underestimated. Even though var(c i ) was underestimated, its corresponding scale parameter τ 5 was not. The mean estimate was equal to 0.5469 (τ 2 5 = 0.5469 2 ≈ 0.2991). The bias in the covariance matrix estimation was introduced due to the underestimation of the parameters in the correlation matrix, but it did not affect the fixed effects in the longitudinal profile and the hazard function. Therefore, this provides a REML-like estimates of the fixed effects that are independent of the variance parameters.
Case study
The proposed joint model was fitted to the Framingham Heart Study data described in Section 2. The longitudinal profile considered was the SBP, and the event of interests was the occurrence of CVD. The objective was to investigate the effect of anti-hypertensive medication on the SBP profile and the variability of the SBP, the indirect effect of the treatment on the risk of developing CVD, and the effect of intra-individual variability on the risk of CVD. CVD event time was considered to be the same as the time of diagnosis rather than the true time of CVD onset of which the information is not available. Though an interval-censored survival model would be more appropriate, the approximation of the true survival time by the diagnosis time at the total time scale suffice to illustrate the usage of the proposed joint model. Furthermore, a Weibull baseline distribution was assumed for the survival model based on the recommendation from the literature (Hu, 2013) . All posterior estimates of the model generated from the MCMC algorithm converged well with the split R-hat statistic (potential scale reduction factor) (Gelman and others, 1992) for all parameters close to 1. Additional graphic inspection of the trace-plots was also performed. Posterior predictive checking (Gelman and others, 1996) The results of the estimates of the fixed effect parameters is summarized in Furthermore, 2 times higher SBP standard deviation is estimated to have a hazard ratio of exp(2 × 0.38 × log 2) ≈ 1.69. Thus the treatment reduces the risk on CVD through the lowering of SBP, it increases the risk of CVD by increasing the variability. Since the effect of the change in variability is larger than the effect of the change in SBP, our results are in line with the finding that patients receiving anti-hypertensive medication still appear to have higher risk of CVD than those not on anti-hypertensive medication with the same SBP level (D'Agostino and others, 2008; Psaty and others, 2001; others, 2003, 2004) . Furthermore, individuals that will immediately benefit from the anti-hypertensive medication are those whose subject-specific reduction of the SBP b 2i satisfy the inequality The estimated correlation matrix (posterior mean) of the five latent variables is presented in Table 5 . A small negative correlation is found between the baseline SBP level (b 0i ) and the slope prior to treatment (b 1i ) which indicates that individuals with higher baseline SBP corresponds to a slower natural growth rate of SBP. It is however more interesting to see that the two effects of the treatment, namely the direct lowering effect on the SBP level (b 2i ) and the reduction of the growth rate of the SBP (b 3i ), are all negatively correlated with the baseline SBP and the growth rate prior to the treatment. Heuristically, this means that individuals with higher baseline SBP and faster SBP increase before treatment is more likely to benefit from the anti-hypertensive medication either by a direct SBP lowering and/or by a larger reduction in the progression after treatment. Furthermore, the correlation between SBP variability and SBP level as mentioned in Section 1, is captured by the large positive correlation between b 0i and c i in Table 5 . Not surprisingly, a higher SBP level is associated with a higher variability and the SBP variability is positively correlated with the growth rate. However, more strikingly, both treatment effects are negatively correlated with the SBP variability, indicating that the anti-hypertensive medication is more beneficial for individuals with a higher SBP variability. Since higher variability corresponds to higher SBP levels and faster progression before treatment, this finding is consistent with the previously presented findings. It should be noted that the parameters in the treatment allocation model were not discussed in the present paper since the treatment allocation model factorizes the likelihood function and it can be ignored. However, it is straightforward to incorporate the treatment allocation model by considering the complete likelihood function instead of the partial likelihood function.
Though a Bayesian framework is adopted, other estimation methods such as the expectation maximization (EM) algorithm and its variations, for instance Monte Carlo EM (Wei and Tanner, 1990 ) and PX-EM (Liu and others, 1998) 
